Mindset Pharma
Mindset Pharma was a Toronto-based drug discovery company developing proprietary serotonin 5-HT2A receptor agonists for treatment-resistant depression and PTSD, acquired by Otsuka Pharmaceutical in Q4 2023.
- Company typePrivate
- Founded2011
- HeadquartersToronto, Canada
- Headcount1–10
- GTM typeB2B
- OfferingServices
What Mindset Pharma does
Mindset Pharma was a Toronto, Canada-based drug discovery and R&D company that developed novel serotonin 5-HT2A receptor agonists — a new class of compounds being investigated as potential therapies for treatment-resistant depression (TRD) and post-traumatic stress disorder (PTSD). The firm's underlying technology centered on proprietary synthesis processes for next-generation psychedelic-inspired small molecules targeting the 5-HT2A receptor, with intellectual property protections around both the compounds and their manufacturing routes. Mindset positioned itself within the broader psychiatric and neurological disorders therapeutic area, addressing indications with explicitly high unmet medical need.
The company's business model was pre-commercial and pre-revenue. With a headcount of 1-10 employees, Mindset operated as a discovery-stage biotech funded by equity capital — most recently a December 2020 financing of approximately $4.17 million — and monetized through licensing/royalty pathways that had not yet materialized prior to the acquisition. The go-to-market motion was partnership-driven rather than sales-driven: the company's primary commercial relationship was a January 2022 joint development agreement with The McQuade Center for Strategic Research and Development (MSRD), an affiliate of Otsuka Pharmaceutical, to co-develop 5-HT2A agonists for TRD and PTSD.
In September 2023, Otsuka Pharmaceutical (via Otsuka America Pharmaceutical, Inc., 'OAI') announced an all-cash acquisition of Mindset Pharma, executed through a Canadian Plan of Arrangement. The transaction closed in Q4 2023, making Mindset a wholly-owned subsidiary of OAI. Following the deal, Otsuka indicated it would continue developing multiple new 5-HT2A agonists across North America and Europe as part of its stated priority focus on psychiatry and neurology.
Mindset Pharma firmographics
Firmographics- Name
- Mindset Pharma
- Legal name
- Mindset Pharma, Inc.
- Website
- https://mindsetpharma.com
- Company type
- Private
- Founded year
- 2011
- Operating status
- Acquired
- Headcount range
- 1–10 employees
- Short description
- Mindset Pharma was a Toronto-based drug discovery company developing proprietary serotonin 5-HT2A receptor agonists for treatment-resistant depression and PTSD, acquired by Otsuka Pharmaceutical in Q4 2023.
- Ownership category
- akta.pro rank
Mindset Pharma industry classification
Industry- Product category
- Psychiatric Drug Discovery
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)
- akta.pro secondary industry
- Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF)
Keywords
Where Mindset Pharma is headquartered
LocationHeadquarters
- HQ city
- Toronto
- HQ country
- Canada
- HQ region
- North America
Markets served
Mindset Pharma business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations
Revenue model
- Pre-Revenue R&D Stage: Mindset Pharma was a drug discovery-based research and development company focused on developing novel therapeutic compounds. The company had not yet commercialized products and was operating through funding and partnership arrangements prior to its acquisition by Otsuka Pharmaceutical in September 2023.
Go-to-market motion1 record
Marketing channels2 records
Mindset Pharma product offering
Product offeringCore offering
Mindset Pharma is a drug discovery-based research and development company focused on developing next-generation therapeutics for psychiatric and neurological disorders. Its primary pipeline consists of novel serotonin 5-HT2A receptor agonists being developed as potential therapies for treatment-resistant depression and post-traumatic stress disorder (PTSD). The company operated through joint development agreements and strategic partnerships, most notably with Otsuka's affiliate MSRD, before being acquired by Otsuka Pharmaceutical in 2023.
Product overview
Mindset Pharma is a drug discovery-based research and development company focused on developing next generation therapeutics for psychiatric and neurological disorders. The company's primary pipeline is centered on 5-HT2A agonists—a new class of compounds targeting the serotonin 5-HT2A receptor. The lead compound is being developed for treatment-resistant depression and PTSD. In September 2023, Otsuka Pharmaceutical announced plans to acquire Mindset Pharma to strengthen its psychiatric and neurological pipeline.
Differentiator
Problem solved
Functional benefit
Products and services
- 5-HT2A Agonist Program A serotonin 5-HT2A receptor agonist drug candidate being developed as a potential therapy for treatment-resistant depression and post-traumatic stress disorder (PTSD). It represents a novel class of agonists for psychiatric and neurological disorders with high unmet medical needs and is intended for development and commercialization by a pharmaceutical partner (Otsuka Pharmaceutical post-acquisition) in North America and Europe.
Quantifiable outcome
- Expected major innovation in psychiatric and neurological disorders field
Companies that use Mindset Pharma
Customer profileSegments1 record
Ideal customer profiles1 record
Mindset Pharma technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Mindset Pharma partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- The McQuade Center for Strategic Research and Development, LLC (MSRD)coreIn January 2022, Mindset and The McQuade Center for Strategic Research and Development, LLC (MSRD), an affiliate of Otsuka that invests in early-stage research programs, entered into a joint development agreement to support Mindset's research and develop a new class of agonists that activate the serotonin 5-HT2A receptor. The collaboration focused on developing compounds for treatment-resistant depression and PTSD.
Scale indicators2 records
Recent moves4 records
Expansion highlights4 records
Mindset Pharma competitors and assessment
Company assessmentEmerging players
- Beckley Psytech: Clinical-stage psychedelic medicine company developing intranasal 5-MeO-DMT and other serotonergic compounds for neuropsychiatric indications. Emerging competitor in the psychedelic CNS space.
- Delix Therapeutics: Preclinical biotech developing non-hallucinogenic psychoplastogens that modulate 5-HT2A receptors for depression and other CNS indications. Comparable as a next-generation 5-HT2A-focused CNS drug discovery company.
Direct peers
- Compass Pathways: Clinical-stage psychedelic medicine company developing psilocybin therapy for treatment-resistant depression. Directly comparable as a psychedelic-derived CNS drug developer targeting the same TRD indication.
- Sage Therapeutics: CNS-focused biopharma developing innovative therapeutics for depression, including NMDA and GABA-modulating approaches. Comparable as a focused CNS drug discovery company targeting TRD and related indications.
- Cybin Inc: Psychedelic drug discovery company developing deuterated tryptamine derivatives targeting 5-HT2A receptors for depression and anxiety disorders. Direct competitor in next-gen psychedelic CNS chemistry.
- GH Research: Clinical-stage company developing mebufotenin (5-MeO-DMT) and other 5-HT2A agonists for treatment-resistant depression. Targets the same receptor pathway and patient population as Mindset.
- MindMed: Psychedelic-inspired CNS drug developer with programs in LSD-derived and other serotonin receptor-targeting compounds for anxiety, depression, and ADHD. Closely aligned with Mindset's 5-HT2A agonist approach.
- ATAI Life Sciences: Clinical-stage biopharma platform company developing psychedelic and non-psychedelic compounds for mental health, including depression and PTSD. Operates a portfolio model similar to how Mindset was structured before acquisition.
Broad incumbents
- Otsuka Pharmaceutical: Global pharmaceutical company and Mindset's acquirer, with designated priority therapeutic areas in psychiatry and neurology including aripiprazole and brexpiprazole. Now the parent of Mindset's pipeline.
- Lundbeck: Global CNS-focused pharmaceutical company partnered with Otsuka on brexpiprazole PTSD trials. Broad incumbent in psychiatry and neurology with overlapping strategic interests in TRD and PTSD.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat2 records
Customer concentration
Mindset Pharma social profiles
Digital presenceMindset Pharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
Mindset Pharma leadership team
Management profileNumber of profiles
Profiles2 records
Mindset Pharma funding detail
Funding detailFunding overview
Funding rounds1 record
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Mindset Pharma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Mindset Pharma
What does Mindset Pharma do?
Mindset Pharma is a drug discovery-based research and development company focused on developing next-generation therapeutics for psychiatric and neurological disorders. Its primary pipeline consists of novel serotonin 5-HT2A receptor agonists being developed as potential therapies for treatment-resistant depression and post-traumatic stress disorder (PTSD). The company operated through joint development agreements and strategic partnerships, most notably with Otsuka's affiliate MSRD, before being acquired by Otsuka Pharmaceutical in 2023.
Is Mindset Pharma a public or private company?
Mindset Pharma is a private company. It is classified as corporate owned and is currently acquired.
When was Mindset Pharma founded?
Mindset Pharma was founded in 2011. It employs 1 to 10 people.
Where is Mindset Pharma based?
Mindset Pharma is headquartered in Toronto, Canada, in the North America region.
How does Mindset Pharma make money?
One revenue line is on record: pre-Revenue R&D Stage.
Who are Mindset Pharma's main competitors?
Emerging players on record are Beckley Psytech and Delix Therapeutics. Direct peers are Compass Pathways, Sage Therapeutics, Cybin Inc, GH Research, MindMed and ATAI Life Sciences. Broad incumbents are Otsuka Pharmaceutical and Lundbeck.
Does Mindset Pharma have an API?
No public API is recorded for Mindset Pharma.
What industry is Mindset Pharma in?
Mindset Pharma's product category is Psychiatric Drug Discovery. Its primary akta.pro industry code is HLAIACAC, Neurology & CNS Specialty Pharmaceuticals, with a secondary code of HLAIAAAF, Neurology & Psychiatry (CNS) Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.